Abstract
A major challenge for cell-based non-invasive prenatal testing (NIPT) is to distinguish individual presumptive fetal cells from maternal cells in female pregnancies. We have sought a rapid, robust, versatile, and low-cost next-generation sequencing method to facilitate this process. Toward this goal, single isolated cells underwent whole genome amplification prior to genotyping. Multiple highly polymorphic genomic regions (including HLA-A and HLA-B) with 10-20 very informative single nucleotide polymorphisms (SNPs) within a 200 bp interval were amplified with a modified method based on other publications. To enhance the power of cell identification, approximately 40 Human Identification SNP (Applied Biosystems) test amplicons were also utilized. This method allowed reliable differentiation of fetal and maternal cells. In fully informative cases, two haplotypes were found within the maternal reads, and fetal cells showed reads with one but not the second maternal haplotype while also showing a novel paternal haplotype absent in the mother. For SNP typing, at least 2 SNPs and 10% of informative SNPs were required to differentiate a fetal cell from a maternal cell. A paternal DNA sample is not required using this method. The assay also successfully detected point mutations causing Tay Sachs disease, cystic fibrosis, and hemoglobinopathies in single lymphoblastoid cells, and monogenic disease-causing mutations in three cell-based NIPT cases. This method could be applicable for any monogenic diagnosis.
Competing Interest Statement
The Houston authors are faculty and staff at Baylor College of Medicine (BCM), which is a partial owner of a for profit diagnostic company, Baylor Genetics (BG); Houston authors also are employee of or have advisory or lab director roles at BG. ALB is founder and CEO of Luna Genetics, Inc.
Funding Statement
This work was supported by internal institutional funds at Baylor College of Medicine. We thank the participating patients, study coordinators, and genetic counselors at Baylor College of Medicine, Texas Children's Hospital, and Columbia University Medical Center for recruitment of samples.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Blood samples from pregnant women were collected after informed consent, under a protocol approved by the Institutional Review Boards of Baylor College of Medicine and Columbia University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files. Raw data is available upon request according to IRB requirement.
